Literature DB >> 29718460

Age Moderates Smokers' Subjective Response to Very-Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial.

Rachel N Cassidy1, Jennifer W Tidey1, Qing Cao2, Suzanne M Colby1, Francis J McClernon3, Joseph S Koopmeiners2, Dorothy Hatsukami2, Eric C Donny4.   

Abstract

INTRODUCTION: Reducing the level of nicotine in cigarettes is a regulatory strategy that has the potential to greatly improve public health. If nicotine levels are reduced in all commercially available cigarettes, current smokers might find it easier to quit and young people might be less likely to become dependent. However, it is not yet known whether age moderates subjective or behavioral responses to low-nicotine cigarettes.
METHODS: Recently, a large, multisite randomized clinical trial was conducted to compare the effects of cigarettes differing in nicotine content (either usual-brand or research cigarettes containing 15.8, 5.2, 2.4, 1.3, or 0.4 mg nicotine/g tobacco) across 6 weeks of exposure. In this secondary analysis, we tested whether age moderated smokers' subjective (measures of psychological reward, smoking satisfaction) and behavioral (cigarettes smoked per day, smoking topography, and nicotine exposure) responses to cigarettes varying in nicotine content after 2 and 6 weeks of use, while controlling for baseline dependence and demographic factors.
RESULTS: Results indicated that younger adults (age 18-24) who smoked cigarettes with 2.4-0.4 mg/g nicotine reported significantly less smoking satisfaction and psychological reward, and smoked fewer cigarettes per day, than older adults (25+ years) after 2 weeks of use. No differences in topography were observed at either time point. After 6 weeks of use, differences had diminished on all measures.
CONCLUSIONS: The reduced positive effects of reduced-nicotine content cigarettes in young adults suggests that this regulatory policy may reduce smoking reinforcement in this vulnerable population. IMPLICATIONS: As the FDA considers reducing the level of nicotine in cigarettes to make them less addictive, understanding the potential impact of this policy on young people is of crucial importance. We found that young adults had significantly lower positive subjective effects to very-low nicotine content (VLNC) cigarettes and smoked fewer VLNC cigarettes than older adults after 2 weeks of use, indicating that this policy may reduce smoking reinforcement more quickly in young adults. These data add to the growing body of evidence on the potential for this policy to positively affect public health.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29718460      PMCID: PMC6588393          DOI: 10.1093/ntr/nty079

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  32 in total

1.  A review of positive conditioned reinforcement.

Authors:  R T KELLEHER; L R GOLLUB
Journal:  J Exp Anal Behav       Date:  1962-10       Impact factor: 2.468

2.  Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking.

Authors:  Jesse Dallery; Elisabeth J Houtsmuller; Wallace B Pickworth; Maxine L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  2002-10-31       Impact factor: 4.530

Review 3.  Adolescent brain maturation and smoking: what we know and where we're headed.

Authors:  David M Lydon; Stephen J Wilson; Amanda Child; Charles F Geier
Journal:  Neurosci Biobehav Rev       Date:  2014-07-12       Impact factor: 8.989

4.  A Nicotine-Focused Framework for Public Health.

Authors:  Scott Gottlieb; Mitchell Zeller
Journal:  N Engl J Med       Date:  2017-08-16       Impact factor: 91.245

5.  Establishing a nicotine threshold for addiction. The implications for tobacco regulation.

Authors:  N L Benowitz; J E Henningfield
Journal:  N Engl J Med       Date:  1994-07-14       Impact factor: 91.245

6.  Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes.

Authors:  August R Buchhalter; Michelle C Acosta; Sarah E Evans; Alison B Breland; Thomas Eissenberg
Journal:  Addiction       Date:  2005-04       Impact factor: 6.526

7.  Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game.

Authors:  Neal L Benowitz; Eric C Donny; Dorothy K Hatsukami
Journal:  Addiction       Date:  2016-08-23       Impact factor: 6.526

Review 8.  Nicotine and the adolescent brain.

Authors:  Menglu Yuan; Sarah J Cross; Sandra E Loughlin; Frances M Leslie
Journal:  J Physiol       Date:  2015-06-23       Impact factor: 5.182

9.  Cigarette prohibition and the need for more prior testing of the WHO TobReg's global nicotine-reduction strategy.

Authors:  Lynn T Kozlowski
Journal:  Tob Control       Date:  2016-06-29       Impact factor: 7.552

Review 10.  Reducing the nicotine content to make cigarettes less addictive.

Authors:  Neal L Benowitz; Jack E Henningfield
Journal:  Tob Control       Date:  2013-05       Impact factor: 7.552

View more
  16 in total

1.  The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller.

Authors:  Dorothy K Hatsukami; Eric C Donny
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 2.  Research on Youth and Young Adult Tobacco Use, 2013-2018, From the Food and Drug Administration-National Institutes of Health Tobacco Centers of Regulatory Science.

Authors:  Cheryl L Perry; MeLisa R Creamer; Benjamin W Chaffee; Jennifer B Unger; Erin L Sutfin; Grace Kong; Ce Shang; Stephanie L Clendennen; Suchitra Krishnan-Sarin; Mary Ann Pentz
Journal:  Nicotine Tob Res       Date:  2020-06-12       Impact factor: 4.244

3.  Construct validity of the Cigarette Ratings Scale and associations with tobacco use and product feature outcomes.

Authors:  Andrea C Johnson; Melissa Mercincavage; Valentina Souprountchouk; Anupreet K Sidhu; Andrea C Villanti; Cristine D Delnevo; Andrew A Strasser
Journal:  Drug Alcohol Depend       Date:  2022-03-08       Impact factor: 4.852

Review 4.  Tobacco harm reduction: Past history, current controversies and a proposed approach for the future.

Authors:  Dorothy K Hatsukami; Dana M Carroll
Journal:  Prev Med       Date:  2020-04-23       Impact factor: 4.018

Review 5.  Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors.

Authors:  Cassidy M White; Dorothy K Hatsukami; Eric C Donny
Journal:  Neuropharmacology       Date:  2020-06-12       Impact factor: 5.250

6.  Do non-daily smokers compensate for reduced cigarette consumption when smoking very-low-nicotine-content cigarettes?

Authors:  Saul Shiffman; Jason M Mao; Brenda F Kurland; Sarah M Scholl
Journal:  Psychopharmacology (Berl)       Date:  2018-10-05       Impact factor: 4.530

7.  Pharmacokinetic Profile of Spectrum Reduced Nicotine Cigarettes.

Authors:  Helen M Kamens; Constanza P Silva; Russell T Nye; Carley N Miller; Nayantara Singh; Joseph Sipko; Neil Trushin; Dongxiao Sun; Steven A Branstetter; Joshua E Muscat; John P Richie; Jonathan Foulds
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

8.  The Impact of Nicotine Dose on the Reinforcing Value of Cigarettes in Adolescents.

Authors:  Rachel N Cassidy; Mollie E Miller; Jennifer W Tidey; Graham DiGuiseppi; Rachel L Denlinger-Apte; Suzanne M Colby
Journal:  Tob Regul Sci       Date:  2019-03

9.  Reactions to reduced nicotine content cigarettes in a sample of young adult, low-frequency smokers.

Authors:  Maggie M Sweitzer; Lauren R Pacek; Rachel V Kozink; Erin Locey; Scott H Kollins; Eric C Donny; F Joseph McClernon
Journal:  Psychopharmacology (Berl)       Date:  2021-05-12       Impact factor: 4.415

10.  Regulatory Approaches and Implementation of Minimally Addictive Combusted Products.

Authors:  Dorothy K Hatsukami; Dongqun Xu; Geoffrey Ferris Wayne
Journal:  Nicotine Tob Res       Date:  2022-03-01       Impact factor: 5.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.